Search research articles
Contact Us
Filters
Showing results (341-350 of 377) with videos related to
Page
of 38
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 21, 2021
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
Jeremie Calais, Andrei Gafita, Matthias Eiber, et al.
BMC Cancer
|
May 1, 2020
Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy
Ann-Kathrin Oehus, Stephanie G C Kroeze, Nina-Sophie Schmidt-Hegemann, et al.
European Urology Oncology
|
May 10, 2024
Biochemical Response of <0.1 ng/ml Predicts Therapy-free Survival of Prostate Cancer Patients following Prostate-specific Membrane Antigen-targeted Salvage Surgery
Sophie Knipper, Flemming Lischewski, Daniel Koehler, et al.
The Lancet. Oncology
|
August 1, 2024
Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study
Madeleine J Karpinski, Johannes Hüsing, Kevin Claassen, et al.
European Urology
|
March 15, 2024
Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study
Manuel Weber, Wolfgang P Fendler, Aravind S Ravi Kumar, et al.
BJUI Compass
|
August 28, 2023
A randomised trial of [<sup>18</sup>F]PSMA-1007-PET/CT versus NaF-PET/CT for staging primary prostate cancer: A trial protocol
Karen Middelbo Buch-Olsen, Mads Hvid Poulsen, Steinbjørn Hansen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 15, 2017
<sup>68</sup>Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study
Wolfgang Peter Fendler, Jeremie Calais, Martin Allen-Auerbach, et al.
The Lancet. Oncology
|
August 4, 2019
<sup>18</sup>F-fluciclovine PET-CT and <sup>68</sup>Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial
Jeremie Calais, Francesco Ceci, Matthias Eiber, et al.
EMBO Molecular Medicine
|
February 4, 2022
Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems
Katja Peschke, Hannah Jakubowsky, Arlett Schäfer, et al.
The Lancet. Oncology
|
July 11, 2021
Nomograms to predict outcomes after <sup>177</sup>Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study
Andrei Gafita, Jeremie Calais, Tristan R Grogan, et al.
Page
of 38
Search research articles
Search
Showing results (341-350 of 377) with videos related to
Sort By:
Page
of 38
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 21, 2021
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
Jeremie Calais, Andrei Gafita, Matthias Eiber, et al.
BMC Cancer
|
May 1, 2020
Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy
Ann-Kathrin Oehus, Stephanie G C Kroeze, Nina-Sophie Schmidt-Hegemann, et al.
European Urology Oncology
|
May 10, 2024
Biochemical Response of <0.1 ng/ml Predicts Therapy-free Survival of Prostate Cancer Patients following Prostate-specific Membrane Antigen-targeted Salvage Surgery
Sophie Knipper, Flemming Lischewski, Daniel Koehler, et al.
The Lancet. Oncology
|
August 1, 2024
Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study
Madeleine J Karpinski, Johannes Hüsing, Kevin Claassen, et al.
European Urology
|
March 15, 2024
Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study
Manuel Weber, Wolfgang P Fendler, Aravind S Ravi Kumar, et al.
BJUI Compass
|
August 28, 2023
A randomised trial of [<sup>18</sup>F]PSMA-1007-PET/CT versus NaF-PET/CT for staging primary prostate cancer: A trial protocol
Karen Middelbo Buch-Olsen, Mads Hvid Poulsen, Steinbjørn Hansen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 15, 2017
<sup>68</sup>Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study
Wolfgang Peter Fendler, Jeremie Calais, Martin Allen-Auerbach, et al.
The Lancet. Oncology
|
August 4, 2019
<sup>18</sup>F-fluciclovine PET-CT and <sup>68</sup>Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial
Jeremie Calais, Francesco Ceci, Matthias Eiber, et al.
EMBO Molecular Medicine
|
February 4, 2022
Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems
Katja Peschke, Hannah Jakubowsky, Arlett Schäfer, et al.
The Lancet. Oncology
|
July 11, 2021
Nomograms to predict outcomes after <sup>177</sup>Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study
Andrei Gafita, Jeremie Calais, Tristan R Grogan, et al.
Page
of 38